- Home
- EPOW vs BRNS Comparison
EPOW vs BRNS Comparison
Compare EPOW & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPOW | BRNS |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 24.1M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EPOW | BRNS |
|---|---|---|
| Price | $0.71 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 423.0K | 17.6K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.57 | $0.51 |
| 52 Week High | $1.86 | $2.91 |
Technical Indicators
Market Signals| Indicator | EPOW | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 64.08 |
| Support Level | N/A | $0.66 |
| Resistance Level | $1.05 | $0.76 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 29.71 | 77.24 |
Price Performance
Historical ComparisonAbout EPOW Sunrise New Energy Co. Ltd
E Power Inc, through its subsidiaries, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. The company operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant's low production costs and reduced environmental impact in the production of graphite anode materials. Additionally, it also operates a knowledge sharing platform business.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.